These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 15207281

  • 1. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys.
    Samadi P, Grégoire L, Bédard PJ.
    Neurobiol Dis; 2004 Jun; 16(1):246-53. PubMed ID: 15207281
    [Abstract] [Full Text] [Related]

  • 2. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [Abstract] [Full Text] [Related]

  • 3. Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys.
    Samadi P, Grégoire L, Rouillard C, Bédard PJ.
    Neurobiol Dis; 2005 Jul; 19(1-2):266-72. PubMed ID: 15837582
    [Abstract] [Full Text] [Related]

  • 4. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E.
    Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
    [Abstract] [Full Text] [Related]

  • 5. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M.
    Neuroscience; 2005 May; 132(2):409-20. PubMed ID: 15802193
    [Abstract] [Full Text] [Related]

  • 6. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P, Lévesque M, Morissette M, Calon F, Dridi M, Di Paolo T, Parent A.
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [Abstract] [Full Text] [Related]

  • 7. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):446-54. PubMed ID: 20026151
    [Abstract] [Full Text] [Related]

  • 8. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G, Morissette M, Parent M, Di Paolo T.
    Eur J Neurosci; 2011 May 16; 33(10):1823-31. PubMed ID: 21501255
    [Abstract] [Full Text] [Related]

  • 9. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.
    Neuropharmacology; 2005 Aug 16; 49(2):165-73. PubMed ID: 15996565
    [Abstract] [Full Text] [Related]

  • 10. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Mov Disord; 2006 Jan 16; 21(1):9-17. PubMed ID: 16127720
    [Abstract] [Full Text] [Related]

  • 11. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
    Samadi P, Grégoire L, Bédard PJ.
    Neuropharmacology; 2003 Dec 16; 45(7):954-63. PubMed ID: 14573388
    [Abstract] [Full Text] [Related]

  • 12. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
    Samadi P, Grégoire L, Rassoulpour A, Guidetti P, Izzo E, Schwarcz R, Bédard PJ.
    Mov Disord; 2005 Jul 16; 20(7):792-802. PubMed ID: 15954116
    [Abstract] [Full Text] [Related]

  • 13. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Grégoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T.
    Parkinsonism Relat Disord; 2013 May 16; 19(5):508-14. PubMed ID: 23402994
    [Abstract] [Full Text] [Related]

  • 14. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.
    Biol Psychiatry; 2009 Sep 15; 66(6):603-13. PubMed ID: 19520364
    [Abstract] [Full Text] [Related]

  • 15. DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
    Bélanger N, Grégoire L, Bédard PJ, Di Paolo T.
    Neurobiol Aging; 2006 Nov 15; 27(11):1684-93. PubMed ID: 16253392
    [Abstract] [Full Text] [Related]

  • 16. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    Hadj Tahar A, Ekesbo A, Grégoire L, Bangassoro E, Svensson KA, Tedroff J, Bédard PJ.
    Eur J Pharmacol; 2001 Feb 02; 412(3):247-54. PubMed ID: 11166288
    [Abstract] [Full Text] [Related]

  • 17. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb 02; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 18. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
    Langston JW, Quik M, Petzinger G, Jakowec M, Di Monte DA.
    Ann Neurol; 2000 Apr 02; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
    [Abstract] [Full Text] [Related]

  • 19. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M.
    Synapse; 2008 Jul 02; 62(7):524-33. PubMed ID: 18435422
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.